Safety of megadose meropenem in the empirical treatment of nosocomial sepsis: a pilot randomized clinical trial

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Singer M, Deutschman CS, Seymour CW et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 315, 801–810 (2016).
  Medline CASGoogle Scholar
• 2. Rello J, Valenzuela-Sánchez F, Ruiz-Rodriguez M et al. Comparison of two empirical prolonged infusion dosing regimens for meropenem in patients with septic shock: a two-center pilot study. Int. J. Antimicrob. Agents 57, 106289 (2021).
  MedlineGoogle Scholar
• 3. Pravda J. Sepsis: Evidence-based pathogenesis and treatment. World J Crit Care Med. 10, 66–80 (2021).
  MedlineGoogle Scholar
• 4. Varon J, Baron RM. A current appraisal of evidence for the approach to sepsis and septic shock. Ther. Adv. Infect. Dis. 6, 2049936119856517 (2019).
  Google Scholar
• 5. Roberts JA, Abdul-Aziz MH, Davis JS et al. Continuous versus intermittent β-lactam infusion in severe sepsis. A meta-analysis of individual patient data from randomized trials. Am. J. Respir. Crit. Care Med. 194, 681–691 (2016).
  Medline CASGoogle Scholar
• 6. Masich AM, Heavner MS, Gonzales JP et al. Pharmacokinetic/pharmacodynamic considerations of beta-lactam antibiotics in adult critically ill patients. Curr. Infect. Dis. Rep. 20, 9 (2018). • Discusses the pharmacokinetics (PKs) and pharmacodynamics (PDs) of β-lactam antibiotics.
  MedlineGoogle Scholar
• 7. Rizk NA, Kanafani ZA, Tabaja HZ et al. Extended infusion of beta-lactam antibiotics: optimizing therapy in critically-ill patients in the era of antimicrobial resistance. Expert Rev. Anti Infect. Ther. 15, 645–652 (2017).
  Medline CASGoogle Scholar
• 8. Jaruratanasirikul S, Thengyai S, Wongpoowarak W et al. Population pharmacokinetics and Monte Carlo dosing simulations of meropenem during the early phase of severe sepsis and septic shock in critically ill patients in intensive care units. Antimicrob. Agents Chemother. 59, 2995–3001 (2015).
  Medline CASGoogle Scholar
• 9. Kitzes-Cohen R, Farin D, Piva G et al. Pharmacokinetics and pharmacodynamics of meropenem in critically ill patients. Int. J. Antimicrob. Agents 19, 105–110 (2002).
  Medline CASGoogle Scholar
• 10. Wang S, Zhao SY, Xiao SZ et al. Antimicrobial resistance and molecular epidemiology of Escherichia coli causing bloodstream infections in three hospitals in Shanghai, China. PLOS ONE 11, e0147740 (2016).
  MedlineGoogle Scholar
• 11. Goodman KE, Lessler J, Cosgrove SE et al. A clinical decision tree to predict whether a bacteremic patient is infected with an extended-spectrum β-lactamase-producing organism. Clin. Infect. Dis. 63, 896–903 (2016).
  Medline CASGoogle Scholar
• 12. Garnacho-Montero J, Amaya-Villar R. The problem of multi-resistance in Gram-negative bacilli in intensive care units: treatment and prevention strategies. Med. Intensiva (Engl. Ed.) 46, 326–335 (2022).
  Medline CASGoogle Scholar
• 13. Lertwattanachai T, Montakantikul P, Tangsujaritvijit V et al. Clinical outcomes of empirical high-dose meropenem in critically ill patients with sepsis and septic shock: a randomized controlled trial. J. Intensive Care 8, 26 (2020). •• Discusses high-dose meropenem outcomes in critically ill patients.
  MedlineGoogle Scholar
• 14. Thabit AK, Hobbs ALV, Guzman OE, Shea KM. The pharmacodynamics of prolonged infusion β-lactams for the treatment of Pseudomonas aeruginosa infections: a systematic review. Clin. Ther. 41, 2397–2415.e8 (2019). • Discusses PDs of prolonged infusion of β-lactams.
  Medline CASGoogle Scholar
• 15. Nicolau DP. Pharmacokinetic and pharmacodynamic properties of meropenem. Clin. Infect. Dis. 47(Suppl. 1), S32–S40 (2008).
  Medline CASGoogle Scholar
• 16. Salehi M, Jafari S, Ghafouri L et al. Ventilator-associated pneumonia: multidrug resistant Acinetobacter versus extended spectrum beta lactamase-producing Klebsiella. J. Infect. Dev. Ctries 14, 660–663 (2020).
  Medline CASGoogle Scholar
• 17. Jafari Z, Harati AA, Haeili M et al. Molecular epidemiology and drug resistance pattern of carbapenem-resistant Klebsiella pneumoniae isolates from Iran. Microb. Drug Resist. 25, 336–343 (2019).
  Medline CASGoogle Scholar
• 18. Klein Klouwenberg PMC, Ong DS, Bos LD et al. Interobserver agreement of centers for disease control and prevention criteria for classifying infections in critically ill patients. Crit. Care Med. 41, 2373–2378 (2013).
  MedlineGoogle Scholar
• 19. Levy MM, Evans LE, Rhodes A. The Surviving Sepsis Campaign Bundle: 2018 update. Intensive Care Med. 44, 925–928 (2018). • Discusses the Surviving Sepsis Campaign Bundle.
  Medline CASGoogle Scholar
• 20. Davoudi-Monfared E, Khalili H. The threat of carbapenem-resistant Gram-negative bacteria in a Middle East region. Infect. Drug Resist. 11, 1831–1880 (2018).
  Medline CASGoogle Scholar
• 21. Tamma PD, Aitken SL, Bonomo RA et al. Infectious Diseases Society of America guidance on the treatment of extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). Clin. Infect. Dis. 72, e169–e183 (2021).
  Medline CASGoogle Scholar
• 22. Bochud PY, Calandra T. Pathogenesis of sepsis: new concepts and implications for future treatment. BMJ 326, 262–266 (2003).
  Medline CASGoogle Scholar
• 23. Glauser MP, Zanetti G, Baumgartner JD et al. Septic shock: pathogenesis. Lancet 338, 732–736 (1991).
  Medline CASGoogle Scholar
• 24. Fleck A, Raines G, Hawker F et al. Increased vascular permeability: a major cause of hypoalbuminaemia in disease and injury. Lancet 1, 781–784 (1985).
  Medline CASGoogle Scholar
• 25. Varghese JM, Roberts JA, Lipman J. Antimicrobial pharmacokinetic and pharmacodynamic issues in the critically ill with severe sepsis and septic shock. Crit. Care Clin. 27, 19–34 (2011).
  Medline CASGoogle Scholar
• 26. Novelli A, Adembri C, Livi P et al. Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis. Clin. Pharmacokinet. 44, 539–549 (2005).
  Medline CASGoogle Scholar
• 27. Mouton JW, Vinks AA. Is continuous infusion of beta-lactam antibiotics worthwhile; efficacy and pharmacokinetic considerations. J. Antimicrob. Chemother. 38, 5–15 (1996).
  Medline CASGoogle Scholar
• 28. Burgess DS. Pharmacodynamic principles of antimicrobial therapy in the prevention of resistance. Chest 115, 19S–23S (1999).
  Medline CASGoogle Scholar
• 29. Roberts JA, Paul SK, Akova M et al. DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? Clin. Infect. Dis. 58, 1072–1083 (2014).
  Medline CASGoogle Scholar
• 30. Roberts JA, Ulldemolins M, Roberts MS et al. Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept. Int. J. Antimicrob. Agents 36, 332–339 (2010).
  Medline CASGoogle Scholar
• 31. Cojutti PG, Gatti M, Rinaldi M et al. Impact of maximizing Css/MIC ratio on efficacy of continuous infusion meropenem against documented Gram-negative infections in critically ill patients and population pharmacokinetic/pharmacodynamic analysis to support treatment optimization. Front. Pharmacol. 12, 781892 (2021).
  MedlineGoogle Scholar
• 32. Codina MS, Gatti M, Troisi C et al. Relationship between pharmacokinetic/pharmacodynamic target attainment and microbiological outcome in critically ill COVID-19 patients with documented Gram-negative superinfections treated with TDM-guided continuous-infusion meropenem. Pharmaceutics 14, 1585 (2022). •• Discusses the relationship between PKs/PDs and outcome.
  MedlineGoogle Scholar
• 33. Busse D, Simon P, Schmitt L et al. Comparative plasma and interstitial tissue fluid pharmacokinetics of meropenem demonstrate the need for increasing dose and infusion duration in obese and non-obese patients. Clin. Pharmacokinet. 61, 655–672 (2022).
  Medline CASGoogle Scholar
• 34. Delattre IK, Taccone FS, Jacobs F et al. Optimizing β-lactams treatment in critically-ill patients using pharmacokinetics/pharmacodynamics targets: are first conventional doses effective? Expert Rev. Anti Infect. Ther. 15, 677–688 (2017).
  Medline CASGoogle Scholar
• 35. Peters-Sengers H, Butler JM, Uhel F et al. Source-specific host response and outcomes in critically ill patients with sepsis: a prospective cohort study. Intensive Care Med. 48, 92–102 (2022).
  Medline CASGoogle Scholar
• 36. Davenport EE, Burnham KL, Radhakrishnan J et al. Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study. Lancet Respir. Med. 4, 259–271 (2016).
  MedlineGoogle Scholar
• 37. Seymour CW, Kennedy JN, Wang S et al. Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis. JAMA 321, 2003–2017 (2019).
  Medline CASGoogle Scholar
• 38. Fohner AE, Greene JD, Lawson BL et al. Assessing clinical heterogeneity in sepsis through treatment patterns and machine learning. J. Am. Med. Inform. Assoc. 26, 1466–1477 (2019).
  MedlineGoogle Scholar